1. Home
  2. TPCS vs ALXO Comparison

TPCS vs ALXO Comparison

Compare TPCS & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TPCS
  • ALXO
  • Stock Information
  • Founded
  • TPCS 1956
  • ALXO 2015
  • Country
  • TPCS United States
  • ALXO United States
  • Employees
  • TPCS N/A
  • ALXO N/A
  • Industry
  • TPCS Metal Fabrications
  • ALXO Biotechnology: Pharmaceutical Preparations
  • Sector
  • TPCS Industrials
  • ALXO Health Care
  • Exchange
  • TPCS Nasdaq
  • ALXO Nasdaq
  • Market Cap
  • TPCS 51.4M
  • ALXO 56.8M
  • IPO Year
  • TPCS N/A
  • ALXO 2020
  • Fundamental
  • Price
  • TPCS $5.36
  • ALXO $1.07
  • Analyst Decision
  • TPCS
  • ALXO Strong Buy
  • Analyst Count
  • TPCS 0
  • ALXO 6
  • Target Price
  • TPCS N/A
  • ALXO $3.30
  • AVG Volume (30 Days)
  • TPCS 60.2K
  • ALXO 872.6K
  • Earning Date
  • TPCS 08-21-2025
  • ALXO 11-06-2025
  • Dividend Yield
  • TPCS N/A
  • ALXO N/A
  • EPS Growth
  • TPCS N/A
  • ALXO N/A
  • EPS
  • TPCS N/A
  • ALXO N/A
  • Revenue
  • TPCS $33,424,000.00
  • ALXO N/A
  • Revenue This Year
  • TPCS N/A
  • ALXO N/A
  • Revenue Next Year
  • TPCS N/A
  • ALXO N/A
  • P/E Ratio
  • TPCS N/A
  • ALXO N/A
  • Revenue Growth
  • TPCS 3.78
  • ALXO N/A
  • 52 Week Low
  • TPCS $2.05
  • ALXO $0.40
  • 52 Week High
  • TPCS $6.25
  • ALXO $2.36
  • Technical
  • Relative Strength Index (RSI)
  • TPCS 53.99
  • ALXO 55.04
  • Support Level
  • TPCS $5.10
  • ALXO $1.01
  • Resistance Level
  • TPCS $5.50
  • ALXO $1.27
  • Average True Range (ATR)
  • TPCS 0.23
  • ALXO 0.11
  • MACD
  • TPCS -0.33
  • ALXO -0.03
  • Stochastic Oscillator
  • TPCS 93.21
  • ALXO 35.48

About TPCS TechPrecision Corporation Common stock

Techprecision Corp manufactures metal fabricated and machined precision components and systems. It offers a full range of services required to transform raw materials into precision finished products. The company's products are used in markets including defense, aerospace, nuclear, medical, and precision industries. All of its operations and customers are located in the United States. The company have two wholly owned subsidiaries that are each reportable segments: Ranor and Stadco. Each reportable segment focuses on the manufacture and assembly of specific components. It derives maximum revenue from Ranor segment.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: